Hainan Haochuang Pharmaceutical

Hainan Haochuang Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Haikou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on oncology and hematology, targeting signaling pathways critical to cancer progression. Its lead candidate, HC-1110, is a potent dual inhibitor of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3 (FLT3). HC-1110 is currently undergoing Phase 1/2 clinical trials for the treatment of myelofibrosis and acute myeloid leukemia. Hainan Haochuang leverages its internal R&D capabilities to address significant unmet medical needs in the Chinese and global markets. The company is situated within the Haikou National High-tech Zone, benefiting from regional biotech infrastructure.